{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:20:14Z","timestamp":1789968014028,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.humpath.2017.03.023","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T22:00:27Z","timestamp":1492120827000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients"],"prefix":"10.1016","volume":"64","author":[{"given":"Luc","family":"Xerri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Venstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Canioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chassagne-Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues-Cuill\u00e9res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Charlotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Gelas-Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Bolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Punnoose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.03.023_bb0005","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/10428194.2012.734616","article-title":"Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century","volume":"54","author":"Pulte","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2017.03.023_bb0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2017.03.023_bb0015","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0020","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2017.03.023_bb0025","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","article-title":"Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation","volume":"31","author":"Kiaii","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0030","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2017.03.023_bb0035","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1\u2013positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0040","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0045","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0050","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1\u2013positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0055","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.humpath.2012.03.025","article-title":"The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease","volume":"43","author":"Koch","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0060","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2017.03.023_bb0070","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","article-title":"T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab","volume":"17","author":"Wahlin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0075","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bjc.2015.291","article-title":"Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma","volume":"113","author":"Nelson","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2017.03.023_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","article-title":"The microenvironment in follicular lymphoma","volume":"24","author":"de Jong","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0085","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1002\/ijc.28937","article-title":"Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma","volume":"135","author":"Voo","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2017.03.023_bb0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.2008.057257","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg lymphoma biomarker consortium)","volume":"62","author":"de Jong","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2013.095257","article-title":"The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg lymphoma biomarker consortium","volume":"99","author":"Sander","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2017.03.023_bb0100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1469-7580.2008.00910.x","article-title":"Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure","volume":"212","author":"Lejeune","year":"2008","journal-title":"J Anat"},{"key":"10.1016\/j.humpath.2017.03.023_bb0105","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1002\/pmic.200800936","article-title":"Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis","volume":"9","author":"Decaestecker","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.humpath.2017.03.023_bb0110","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0120","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2017.03.023_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: a revolutionary tool for transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.humpath.2017.03.023_bb0135","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0140","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"Voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1479-5876-10-205","article-title":"Cancer classification using the Immunoscore: a worldwide task force","volume":"10","author":"Galon","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.humpath.2017.03.023_bb0150","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","article-title":"Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study","volume":"118","author":"Laurent","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2017.03.023_bb0155","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-15-2023","article-title":"Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells","volume":"22","author":"Nielsen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.03.023_bb0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2017.03.023_bb0165","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.4049\/jimmunol.178.7.4051","article-title":"Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3\/CD28-costimulated autologous and allogeneic CD8+CD25\u2212 and CD4+CD25\u2212 T cells","volume":"178","author":"Hilchey","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0170","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/cmi.2012.34","article-title":"Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model","volume":"9","author":"Dou","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.humpath.2017.03.023_bb0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semcancer.2012.03.004","article-title":"What are regulatory T cells (Treg) regulating in cancer and why?","volume":"22","author":"Whiteside","year":"2012","journal-title":"Semin Cancer Biol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717301119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717301119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T14:28:15Z","timestamp":1535898495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817717301119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":35,"alternative-id":["S0046817717301119"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.03.023","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}